Delex Pharma today announced the market introduction of Nicardilex 20 mL, the first and only 20 mL vial formulation of Nicardipine Hydrochloride available in the Philippines. This strategic product launch is positioned to address the critical need for efficient and reliable acute blood pressure management within the country's rapidly growing critical care and emergency sectors.
Addressing a Significant and Growing Market Need
The introduction of Nicardilex 20 mL is highly relevant given the severe burden of cardiovascular diseases in the Philippines, which represents a substantial and growing market for critical care solutions:
- Leading Causes of Mortality: According to the
Philippine Statistics Authority (PSA) data from January to October 2024,
cerebrovascular diseases (including stroke) and ischaemic heart diseases
together constitute the two leading causes of death, underscoring the urgency
for effective hypertensive crisis interventions.
- High-Prevalence Risk Factor: Hypertension, a primary driver of these mortality statistics, affects a considerable and aging segment of the population. Studies highlight that 69.1% of older Filipinos suffer from hypertension, indicating a continuous, high-volume demand for acute management solutions.
Nicardilex 20 mL: Strategic and Operational Advantages
Nicardilex 20 mL is an intravenous formulation of nicardipine, a highly potent calcium channel blocker, indicated for the rapid, short-term management of acute hypertension in critical settings such as stroke, peri-operative care, and hypertensive crises. Its unique formulation provides distinct advantages:
- First-Mover Advantage: As the first and currently only 20 mL nicardipine vial in the local market, Delex Pharma establishes a clear competitive differentiation, potentially capturing significant market share by offering a novel, cost-effective, and clinically efficient dosing option to hospitals and critical care units.
- Enhanced Clinical Utility: The 20 mL presentation is designed to optimize drug preparation and administration protocols, which can lead to reduced wastage, lower overall treatment costs for institutions, and improved efficiency in high-pressure emergency settings.
- Quality Assurance: The product is manufactured by United Biotech Pvt. Ltd. in India, a facility holding internationally recognized WHO-cGMP and ISO 9001:2008 certifications, ensuring a robust and reliable supply chain that meets high standards of quality and safety.
This launch is a key milestone in Delex Pharma's strategy to expand its portfolio of high-value, niche pharmaceuticals that directly address unmet needs in specialized medical fields, reinforcing its position as a dedicated partner in Philippine critical care pharmacotherapy.
About Bounce Mobile Systems, Inc. (BNCM)
On July 2nd. In 2024, the Board of Directors of Bounce Mobile Systems Inc. (BNCM) and Delex Healthcare Group Inc. (DELEX) signed an agreement for the merger between DELEX and BNCM.
About Delex Healthcare Group Inc. (DELEX)
DELEX is a leading pharmaceutical company in the Philippines, engaged in the development, marketing, and distribution of a wide range of pharmaceutical and healthcare products. DELEX is committed to providing quality and affordable medicines and medical devices, with a strong focus on critical care, anti-infectives, anesthesia, oncology, and women's health.
Forward-Looking Statements